Pfizer ‘safe and effective in 12 to 15 year olds’ suggest data
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
The FDA is expected to give the go-ahead to administer shots of the Pfizer vaccine to the youngest cohort yet. Teenagers between ages 12 and 15 may start receiving the jab as early as the end of this week, officials told the New York Times. The shot was authorised for people ages 16 and up in December, and Pfizer has been in trials for teens since October of last year.
The trials of nearly 2,260 volunteers shows Pfizer’s COVID-19 vaccine appears to work in adolescents.
Initial trial results published in March showed there were 18 cases of COVID-19 in people who got a placebo and none in those who got the vaccine.
What’s more, the children showed stronger immune responses to the jab than did the 16 to 25-year-old group Pfizer had previously tested its vaccine in.
Vaccinating children of all ages is seen as being critical to hastening the end of the pandemic.
FDA’s decision will have implications for expanding the eligibility cohort elsewhere.
Authorisation could be given as early as the end of this week, and is expected by early next week.
Pending the regulatory approval, the Centers for Disease Control and Prevention (CDC) will most likely meet the next day and review findings from Pfizer’s trial.
The agency will then recommend whether or not it believes the vaccine is safe and effective for ages 12 to 15.
Fatty liver disease: The warning sign in your pee [INSIGHT]
Type 2 diabetes: The consistency of your stools [TIPS]
People admitted to hosptial after getting Covid vaccine [INSIGHT]
Source: Read Full Article